Innovotech Inc

Healthcare CA IOT

0.1CAD
0.00(0%)

Last update at 2026-06-23T20:00:00Z

Day Range

0.100.10

LowHigh

52 Week Range

0.130.34

LowHigh

Fundamentals

Previous Close 0.10
Market Cap10.34M
Volume10909
P/E Ratio-
Dividend Yield-%
EBITDA0.17M
Revenue TTM4.53M
Revenue Per Share TTM0.09
Gross Profit TTM 2.40M
Diluted EPS TTM-

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Income before tax	0.09M	0.21M	-0.15758M	-0.13651M	0.37M
Minority interest	0.00680M	0.00998M	0.00000M	-	-
Net income	0.09M	0.22M	-0.15758M	-0.13651M	0.37M
Selling general administrative	2.27M	1.01M	0.69M	0.83M	0.82M
Selling and marketing expenses	-	-	-	-	-
Gross profit	2.40M	1.11M	0.48M	0.78M	1.12M
Reconciled depreciation	0.14M	0.06M	0.08M	0.11M	0.07M
Ebit	-	-	-	-	0.27M
Ebitda	-	-	-	-0.01733M	0.44M
Depreciation and amortization	-	-	-	-	-
Non operating income net other	-	-	-	-	-
Operating income	0.02M	0.05M	-0.37967M	-0.14045M	0.27M
Other operating expenses	-	-	-	-	-
Interest expense	0.03M	0.00996M	0.00056M	0.00502M	0.00438M
Tax provision	0.00106M	-	-	-	-
Interest income	0.00886M	0.00299M	0.01M	0.00895M	0.02M
Net interest income	-0.02413M	-0.00697M	0.01M	0.00394M	0.01M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-	-	-	-	-
Total revenue	4.53M	2.19M	1.18M	1.13M	1.48M
Total operating expenses	4.51M	2.15M	1.56M	1.27M	1.21M
Cost of revenue	2.14M	1.08M	0.70M	0.35M	0.36M
Total other income expense net	0.09M	0.17M	0.21M	-	0.09M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	0.09M	0.21M	-0.15758M	-0.13651M	0.37M
Net income applicable to common shares	-	-	-	-	0.37M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total assets	4.43M	3.22M	1.22M	1.22M	1.43M
Intangible assets	0.47M	0.54M	0.16M	-	-
Earning assets	-	-	-	-	-
Other current assets	-	-	-	-	-
Total liab	0.78M	0.60M	0.22M	0.17M	0.26M
Total stockholder equity	3.60M	2.57M	0.93M	1.06M	1.18M
Deferred long term liab	-	-	-	-	-
Other current liab	0.07M	0.07M	-	-	0.03M
Common stock	-	-	-	-	7.70M
Capital stock	9.93M	8.84M	7.70M	7.70M	7.70M
Retained earnings	-8.23048M	-8.32486M	-8.54959M	-8.39201M	-8.25550M
Other liab	-	-	-	-	-
Good will	-	-	-	-	-
Other assets	-	-	-	-	-
Cash	1.62M	0.73M	0.16M	0.47M	0.42M
Cash and equivalents	-	-	-	-	-
Total current liabilities	0.52M	0.42M	0.18M	0.17M	0.22M
Current deferred revenue	-	-	-	-	-
Net debt	-	-	-	-	-
Short term debt	-	-	-	-	-
Short long term debt	-	-	-	-	-
Short long term debt total	-	-	-	-	-
Other stockholder equity	-	-	-	-	0.16M
Property plant equipment	-	-	-	-	0.23M
Total current assets	3.02M	1.68M	0.57M	0.83M	0.99M
Long term investments	-	0.50M	0.33M	0.21M	-
Net tangible assets	-	-	-	-	1.18M
Short term investments	-	0.00000M	0.07M	0.08M	0.07M
Net receivables	0.51M	0.54M	0.20M	0.18M	0.38M
Long term debt	0.16M	-	-	-	-
Inventory	0.19M	0.13M	0.07M	0.04M	0.06M
Accounts payable	0.38M	-	-	-	0.10M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	-	-	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-	-	-	-	-
Deferred long term asset charges	-	-	-	-	-
Non current assets total	1.41M	1.54M	0.65M	0.40M	0.44M
Capital lease obligations	-	-	0.00000M	0.04M	0.12M
Long term debt total	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investments	0.55M	-0.49351M	-0.04287M	-0.07152M	-0.06014M
Change to liabilities	-	-	-	-	-0.02366M
Total cashflows from investing activities	-	-	-	-	-0.06014M
Net borrowings	0.20M	0.00000M	-0.03759M	-	-0.07263M
Total cash from financing activities	0.88M	1.14M	-0.03759M	-0.09022M	-0.07263M
Change to operating activities	-	-	-	-	-0.08833M
Net income	0.09M	0.22M	-0.15758M	-0.13651M	0.37M
Change in cash	0.89M	0.56M	-0.30855M	0.05M	-0.10773M
Begin period cash flow	0.73M	0.16M	0.47M	0.42M	0.53M
End period cash flow	1.62M	0.73M	0.16M	0.47M	0.42M
Total cash from operating activities	-0.06235M	-0.08164M	-0.22808M	0.21M	0.03M
Issuance of capital stock	0.00000M	1.13M	0.00000M	-	0.00000M
Depreciation	0.14M	0.06M	0.08M	0.11M	0.07M
Other cashflows from investing activities	-	-	-	-	-
Dividends paid	0.00000M	0.00000M	0.00000M	-	0.00000M
Change to inventory	-0.05709M	-0.05835M	-0.02786M	0.02M	-0.02090M
Change to account receivables	0.04M	-0.43017M	-0.01940M	0.17M	-0.23671M
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	-	-	-	-	-
Change to netincome	-	-	-	-	-0.04339M
Capital expenditures	0.47M	0.20M	0.04M	0.07M	0.06M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	-0.22574M	-0.20854M	-0.04861M	0.21M	-0.36959M
Stock based compensation	0.12M	0.05M	0.03M	0.02M	0.05M
Other non cash items	-0.09814M	-0.03029M	0.08M	0.00502M	-0.08946M
Free cash flow	-0.53387M	-0.28393M	-0.27096M	0.14M	-0.03510M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (CAD)	Price (CAD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
IOT Innovotech Inc	- -%	0.10	-	-	2.28	2.88	1.96	33.59
SHRX Sharp Therapeutics Corp.	- -%	1.00	-	-	-	32.37
NRX NurExone Biologic Inc.	- -%	0.55	-	6.90	-	15.26	-7.2365
MIR MedMira Inc	-0.005 7.14%	0.07	-	-	223.37	-	293.42	-80.0318
TTI Thiogenesis Therapeutics Corp.	- -%	0.56	-	-	-	15.17	-58.1577

Reports Covered

View All

Profile

Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assay lids; and order biofilm assays. It also provides antimicrobial contract research and antimicrobial testing; antimicrobial and anti-biofilm agents; antimicrobial and anti-biofilm materials; BEST assay testing; implanted medical devices testing; bacteriophage testing; and analytical services. The company serves customers in the areas of biofilm issues, including catheter and implant medical devices, antibiotic drug development, wound healing, paint and specialized coatings, water system antimicrobial agents, dental treatments and water line antimicrobial agents, and bacterial and fungal agricultural crop diseases, as well as disinfectants in food. Innovotech Inc. is headquartered in Edmonton, Canada.

Innovotech Inc

2011-94 Street, Edmonton, AB, Canada, T6N 1H1

780-448-0585
https://innovotech.ca

Key Executives

Name	Title	Year Born
Dr. James Timourian Ph.D.	Chairman, CEO, Pres & Sec.	NA
Mr. Alan C. Savage	CFO & Director	1943
Dr. Tyler Boone	Chief Operating Officer	NA
Dr. Patricia Nadworny	Chief Scientific Officer and Quality & Safety Director	NA
Dr. Merle Olson	Scientific Consultant	NA
Dr. James Timourian Ph.D.	Chairman & Secretary	NA
Dr. Craig Milne B.Sc., M.B.A., Ph.D.	President, CEO & Director	NA
Mr. Bernard Grobbelaar C.A., CPA, CA, CPA	Chief Financial Officer	NA
Dr. Tyler Boone Ph.D.	Chief Operating Officer	NA
Dr. Patricia Nadworny P.Eng., Ph.D.	Chief Scientific Officer and Quality & Safety Director	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.